La cadena de opciones muestra datos clave de las opciones de acciones de Mira Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Mira Pharmaceuticals..

Mira Pharmaceuticals (NASDAQ:MIRA) Bolsa, Cadena de Opciones

Mira Pharmaceuticals

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

MIRA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCOM

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: PDD, DQ, MIRA, HEI y TCOM.

5 acciones en el foco este lunes: PDD, DQ, MIRA, HEI y TCOM

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals Inc

MIRAI Corp

MIRAIT One Corp

MIRAMAR RESOURCES LTD by MIRAMAR RESOURCES LTD

MIRATI THERAPEUTICS INC COM

MIRACLE ENTMT INC by Miracle Entertainment Inc.

Miracle Entertainment Inc

MIRAGE ENERGY CORP by Mirage Energy Corporation

Mirage Energy Corp

MIRAMAR HOTE & INVST CO by Miramar Hotel & Investment Co., Ltd.

Miramar Hotel & Investment Co Ltd

TAKARA LEBEN CO LTD by Takara Leben Co., Ltd.

Mirarth Holdings Inc

MIRASOL RESOURCES LTD by Mirasol Resources Ltd.

Mirasol Resources Ltd

Miratap Inc

MIRAVANT MEDICAL TECHS by Miravant Medical Technologies

Miravant Medical Technologies

Guidance

Centene Expects To Reaffirm Its Previously Issued 2025 Adjusted EPS Guidance Of Greater Than $7.25 (Est $7.23) - Filing

Target Announced The Return Of Target Circle Week March 23-29, Delivering Seven Days Of Exclusive Deals And Up To 40% Off For Members Of The Retailer's Free-to-join Target Circle Program

Nokia Announced That Canal+ Telecom, Will Deploy Its Lightspan And Altiplano Solution To Support The Transformation Of Its Fiber Network Across French Guiana And Guadeloupe

Buybacks

IBTA

Ibotta Plans $100M Increase To Its Share Repurchase Program

National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. The company reported quarterly sales of $343.68 million which missed the analyst consensus estimate of $347.90 million by 1.21 percent.

Earnings Beats

Earnings Misses

NESR

National Energy Services Q4 2025 Adj EPS $0.30 Beats $0.27 Estimate, Sales $343.68M Miss $347.90M Estimate

CLEAR Continues To Expand Locations Outside The Airport Environment To Enroll And Renew Consumers In The Trusted Traveler Program By Opening New Locations At Sawgrass Mills, The Florida Mall, The Galleria, And Lenox Square

On Tuesday, Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) inked a non-binding term sheet with certain lenders to acquire a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264701/rocket-lab-announces-intention-to-acquire-mynaric-leading-laser-communications-provider-in-latest-" rel="noreferrer noopener">controlling stake in </a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264701/rocket-lab-announces-intention-to-acquire-mynaric-leading-laser-communications-provider-in-latest-" rel="noreferrer noopener">Mynaric AG</a>.
Upon execution of a definitive agreement, Rocket Lab would acquire 100% of Mynaric for an initial $75 million, payable in cash or Rocket Lab stock. An additional earn-out of up to $75 million, also in cash or stock, is tied to future revenue targets.
The initial purchase price may increase if the Lenders or affiliates invest more cash in Mynaric post-restructuring, with a corresponding reduction in earn-out potential.
The acquisition is subject to regulatory approvals and the completion of Mynaric&#8217;s ongoing StaRUG restructuring under German law. The transaction is expected to close upon fulfillment of these conditions.
The non-binding term sheet grants Rocket Lab an exclusive negotiation period with the Lenders, subject to due diligence and the execution of a definitive purchase agreement.
Rocket Lab&#8217;s proposed acquisition of Mynaric is driven by their existing partnership, with Mynaric supplying CONDOR Mk3 optical communication terminals for Rocket Lab's $515 million SDA contract to produce 18 satellites.
Rocket Lab aims to scale production and enhance manufacturing efficiencies to ensure timely, cost-effective terminal deliveries for SDA and other clients.
Read: <a target="_blank" href="https://www.benzinga.com/general/space/25/02/44034215/rocket-lab-unveils-flatellite-low-cost-mass-producible-satellite-to-target-large-constellations-amid-weak-q1-guidance" rel="noreferrer noopener">Rocket Lab Unveils &#8216;Flatellite:&#8217; Low-Cost, Mass-Producible Satellite To Target Large Constellations Amid Weak Q1 Guidance</a>
Rocket Lab founder and CEO Sir Peter Beck said, &#8221;Mynaric has paved the way in developing laser technology. Their team and technologies will make a compelling addition to our satellite component portfolio and we look forward to making the technology available at scale for our own constellations and those of our customers.&#8221;
In a separate release, Rocket Lab&nbsp;filed a prospectus supplement with the SEC for an &#8220;at the market&#8221; (ATM) offering of up to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44264676/rocket-lab-announces-at-the-market-atm-equity-offering-program" rel="noreferrer noopener">$500 million in common stock</a>.
The company currently intends to use the net proceeds to fund future growth, including potential acquisitions such as Mynaric and for general corporate and working capital purposes.
Investors can gain exposure to the stock via ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) and Tidal ETF Trust II Pinnacle Focused Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCUS#NYSE">FCUS</a>)
Price Action: RKLB shares are up 1.01% at $18.00 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44253929/space-etfs-rocked-by-intuitive-machines-lunar-mishap-is-there-a-safer-bet" target="_blank" rel="noreferrer noopener">Space ETFs Rocked By Intuitive Machines&#8217; Lunar Mishap — Is There A Safer Bet?</a></li>
</ul>
Image via Shutterstock.

Equities

Large Cap

Contracts

Movers

ARKX

FCUS

RKLB

Rocket Lab Expands Its Space Arsenal: Eyes Laser Tech Boost With Mynaric Buyout

Brenntag (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BNTGY#OTC">BNTGY</a>) reported quarterly earnings of $0.19 per share. This is a 9.52 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $4.26 billion in sales this quarter. This is a 2.05 percent decrease over sales of $4.35 billion the same period last year.

BNTGY

Brenntag Q4 EPS $0.19 Down From $0.21 YoY, Sales $4.26B Down From $4.35B YoY

Morgan Stanley analyst David Arcaro initiates coverage on Talen Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) with a Overweight rating and announces Price Target of $243.

Price Target

Initiation

Analyst Ratings

Morgan Stanley Initiates Coverage On Talen Energy with Overweight Rating, Announces Price Target of $243

U.S. stock futures were up on Wednesday after a volatile session on Tuesday. Futures of all four benchmark indices advanced in premarket trading.
Investors will keep an eye on pivotal February inflation data as stagflation worries have been weighing on Wall Street. Economists polled by TradingEconomics predict a shift in inflation trends, with annual headline inflation expected to drop to 2.9% in February, breaking four months of increases. Monthly price growth is also forecast to slow, as is core inflation, which excludes volatile food and energy costs.
On Tuesday afternoon, President Donald Trump reversed his decision to double tariffs on Canadian steel and aluminum to 50%, just hours after announcing the hike. The sudden shift, which unsettled financial markets, came after a Canadian official withdrew plans for a 25% surcharge on electricity.
Meanwhile, the 10-year Treasury yield stood at 4.27%, while the two-year yield was at 3.94%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 97% chance that the Federal Reserve will keep interest rates unchanged for the March meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.71%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.58%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.41%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was up 0.72% to $559.92, and the QQQ also advanced 0.84% to $475.54, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
The U.S. stock market closed lower on Tuesday after a volatile session. All sectors declined in trade. Industrials, consumer staples, health care and real estate sectors fell over 1%.
On the economic front, small business optimism fell in February, with the NFIB&#8217;s index dropping to 100.7. Uncertainty surged to near-record levels. Additionally, the labor market was strong in January, with rising openings. JOLTS report showed layoffs declining for a fourth straight month to the lowest level since last June.
The S&amp;P 500 index neared correction zone as of Tuesday&#8217;s close, it was 9.36% lower from the previous high of 6,147.43 to 5,572.07 points. Whereas, Nasdaq 100 was 12.80% lower from its 52-week high.
The Dow Jones closed 478 points or 1.14% lower at 41,433.48 on Tuesday, down 8.08% from its previous high.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.18%</td>
<td>17,436.10</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.76%</td>
<td>5,572.07 </td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-1.14%</td>
<td>41,433.48 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.22%</td>
<td>2,023.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Ryan Detrick, the chief market strategist at Carson Research, highlighted in his note &#8216;March Madness,&#8217; that the seasonally the end of February and beginning of March are bound to see weakness.
However, he acknowledged that a correction was at hand, adding, &#8220;We do not expect things to get much worse and the odds of a full-blown bear market remain quite slim. As uncomfortable as this recent volatility feels, know that it is the toll we must pay to invest.&#8221;
According to Ed Yardeni from Yardeni Research, investors were worried about the adverse macroeconomic consequences of all this geopolitical turmoil. &#8220;The uncertainty associated with rapid-fire tariff announcements from the White House could weigh on the economy,&#8221; he said.
As Trump&#8217;s tariffs on steel and aluminum imports take effect, the European Union announced on Wednesday that it would retaliate with levies of 26 billion euros or $28.33 billion on the U.S. goods starting in April in response to the duties.
Highlighting this, economist Mohamed El-Erian hinted at the volatility caused by negotiations between Canada on Tuesday, which will likely translate as a cause of the tensions between the U.S. and EU on Wednesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yesterday&#39;s tariff focus was mainly on the heightened tensions between Canada and US; today, the focus shifts to the EU-US tit-for-tat. (Photo from Bloomberg.)<a href="https://twitter.com/hashtag/economy?src=hash&amp;ref_src=twsrc%5Etfw">#economy</a> <a href="https://twitter.com/hashtag/trade?src=hash&amp;ref_src=twsrc%5Etfw">#trade</a> <a href="https://twitter.com/hashtag/tariffs?src=hash&amp;ref_src=twsrc%5Etfw">#tariffs</a> <a href="https://t.co/KeaknzVr5S">pic.twitter.com/KeaknzVr5S</a>
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1899722713075212796?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Whereas, CNBC&#8217;s Jim Cramer quipped that if the President spoke softly, a decent inflation print would uplift the market.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">a decent CPI and we could have a good run IF President Trump decides to speak softly and carry a big stick
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1899639615834718551?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Wednesday:
<ul>
<li>February&#8217;s core and headline consumer price index data will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Monthly U.S. federal budget data for February will be announced at 2:00 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>E W Scripps Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) surged 37.76% in premarket on Wednesday after it refinanced over $1.3 billion in term loans, secured a new $450 million accounts receivable facility, and a $208 million revolving credit line due 2027.</li>
</ul>
<ul>
<li>Innventure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) zoomed 32.62% secured a three-year white-label agreement with a major thermal management company and launched a new 250kW multi-rack liquid cooling system.</li>
</ul>
<ul>
<li>Stitch Fix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) jumped 18.68% after reporting the fourth quarter revenue of $312.1 million, exceeding expectations, with strong next-quarter guidance of $313.5 million.</li>
</ul>
<ul>
<li>StandardAero Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) dropped 15.87% after reporting a $0.04 loss per share, missing estimates by $0.20, but beat revenue expectations with $1.41 billion, up 21.8% year-on-year.</li>
</ul>
<ul>
<li>Starbox Group Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) plunged 19.45% after receiving a Nasdaq non-compliance notice for failing to maintain a $1.00 minimum bid price, with trading suspension set for March 18, 2025.</li>
</ul>
<ul>
<li>Smith Micro Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) slumped 17.05% after reporting a $0.11 per share adjusted loss. This follows a previous quarter where their $0.30 loss beat estimates by 3.23%.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.68% to hover around $66.70 per barrel.
The gold spot index was up by 0.15% to $2,920.02 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was up 0.07% at the 103.487 level.
Asian markets closed mostly lower on Tuesday except Japan's Nikkei 225, and South Korea's Kospi index. Australia's ASX 200, Hong Kong's Hang Seng, India's S&amp;P BSE Sensex, and China's CSI 300 index declined. European markets were mostly higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44269729/debt-over-equity-billionaire-howard-marks-endorses-credit-investments-amid-shifting-investor-focus-and-market-cor">Billionaire Howard Marks Prefers Credit Over Equity Amid Falling Market: &#8216;Yields Implies Higher Returns From Credit Than The S&amp;P 500&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Market Summary

Futures

Treasuries

Economics

SARO

SFIX

SMSI

STBX

US Stocks Likely To Open Higher Ahead Of February's Inflation Print: Expert Says Odds Of A Full-Blown Bear Market Remain 'Quite Slim'

iRobot Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) &nbsp;announced the availability of a suite of new technologically-innovative Roomba&nbsp;vacuums and 2-in-1 vacuums and mops with advanced features, ranging from debris-compacting systems to extending and retractable dual-spinning mop pads that tackle stubborn messes.

Tech

IRBT

iRobot On Tuesday, Announced Suite of ROOMBA Floor Cleaning Robots

VNET

VNET Expects 2025 Total Net Revenues Of RMB9.10B - RMB9.30B (Est RMB9.075B), Representing Growth Of 10% - 13% YoY

On June 7, 2022, Hello Group's board of directors authorized a share repurchase program under which the Company may repurchase up to US$200 million of its shares up to June 6, 2024 (the "Share Repurchase Program"). On March 14, 2024, Hello Group's board of directors approved to amend the Share Repurchase Program to (i) extend the term of the Share Repurchase Program up to June 30, 2026, and (ii) upsize the Share Repurchase Program to US$286.1 million. On March 12, 2025, Hello Group's board of directors approved an additional amendment to the Share Repurchase Program, to (i) extend the term of the Share Repurchase Program up to March 31, 2027, and (ii) upsize the Share Repurchase Program by another $200 million, so that the Company is authorized to, from time to time, acquire up to an aggregate of US$486.1 million worth of its shares in the form of ADSs and/or the ordinary shares of the Company in the open market and through privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. As of March 12, 2025, after the upsizing of the Share Repurchase Program, the remaining size of the program is US$222 million.

MOMO

Hello Gr Extends Share Buyback Program to March 31, 2027 (From Prior June 30, 2026), Upsizes Total Authorization By $200M to $486 Million

BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) reported quarterly earnings of $0.18 per share. The company reported $140.96 million in sales this quarter.

BingEx Q4 EPADS $0.18, Sales $140.96M

VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.32 by 103.13 percent. The company reported quarterly sales of $307.80 million which missed the analyst consensus estimate of $2.08 billion by 85.17 percent. This is a 15.11 percent increase over sales of $267.39 million the same period last year.

VNET Q4 2024 GAAP EPADS $(0.01), Sales $307.75M

Exane BNP Paribas analyst Nate Crossett upgrades Medical Properties Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>) from Neutral to Outperform and raises the price target from $5 to $9.

Upgrades

Exane BNP Paribas Upgrades Medical Properties Trust to Outperform, Raises Price Target to $9

Hello Group's board of directors has declared a special cash dividend in the amount of US$0.30 per ADS, or US$0.15 per ordinary share. The cash dividend will be paid on April 30, 2025 to shareholders of record at the close of business on April 11, 2025. The ex-dividend date will be April 11, 2025. The aggregate amount of cash dividends to be paid is approximately US$50 million, which will be funded by available cash on the Company's balance sheet.

Dividends

Hello Gr Board Declared A Special Cash Dividend Of $0.30/ADS

B. Riley Securities analyst Yuan Zhi initiates coverage on Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) with a Buy rating and announces Price Target of $15.

RADX

B. Riley Securities Initiates Coverage On Radiopharm Theranostics with Buy Rating, Announces Price Target of $15

Deutsche Bank analyst Brian Bedell maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and lowers the price target from $75 to $61.

HOOD

Deutsche Bank Maintains Buy on Robinhood Markets, Lowers Price Target to $61

BMO Capital analyst Kostas Biliouris initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Outperform rating and announces Price Target of $72.

BMO Capital Initiates Coverage On Avidity Biosciences with Outperform Rating, Announces Price Target of $72

Press Releases

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

Athira Pharma

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Dare Bioscience

Durect

Gelteq

Hoth Therapeutics

Impact BioMedical

IGC Pharma

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

Lyra Therapeutics

ProPhase Labs

Pulmatrix

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Talphera

Traws Pharma

TherapeuticsMD

VYNE Therapeutics

Rodman & Renshaw

Ascendiant Capital

Screenshot 2024-10-02 at 5.44.40 PM

Biotech

General

Screenshot 2024-09-18 at 6.27.57 PM

Screenshot 2024-09-04 at 6.19.41 PM

TELO

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Screenshot 2024-08-26 at 4.53.37 PM

The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End

Screenshot 2024-07-25 at 6.08.16 PM

MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year

Comments

Mira Pharmaceuticals

Mira Pharmaceuticals (MIRA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL